

Title Page

A prospective cohort study of HPV-driven oropharyngeal cancers; implications for prognosis and immunisation

Short title: A population based study of HPV-driven oropharyngeal cancers

Katie Wakeham^{1,2}, Jiafeng Pan³, Kevin G Pollock^{4,5}, David Millan⁶, Sarah Bell⁶, Douglas McLellen⁶, Allan McPhaden⁶, David I Conway⁷, Sheila V Graham⁸, Kim Kavanagh³, Kate Cuschieri⁸

¹Sussex Cancer Centre, Eastern Road, Brighton, BN2 5DA

²Institute of Cancer Sciences, University of Glasgow, Garscube Campus, 464 Bearsden Road, Glasgow G61 1QH

³Department of Mathematics and Statistics, University of Strathclyde, Livingstone Tower, 26 Richmond Street Glasgow, G1 1XH

⁴Vaccine Preventable Disease, Health Protection Scotland, 5 Cadogan Street Glasgow, G2 6QE

⁵Glasgow Caledonian University, School of Health & Life Sciences, Cowcaddens Road, Glasgow, G4 0BA

⁶Department of Pathology, The Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, 1345 Govan Road, Govan, Glasgow, G51 4TF

⁷School of Medicine, Dentistry, and Nursing, University of Glasgow, 378 Sauchiehall Street, Glasgow G3 3JZ

⁸MRC-University of Glasgow Centre for Virus Research, University of Glasgow Sir Michael Stoker Building, Garscube Campus, 464 Bearsden Road Glasgow G61 1QH

⁹Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA

¹ Corresponding author: Dr Katie Wakeham

FRCR PhD

Sussex Cancer Centre,
Eastern Road, Brighton,
BN2 5DA

Telephone: 01273696955

Email: katiwakeham@nhs.net

Research Highlights

- In a population-based cohort of 235 patients diagnosed with oropharyngeal cancer, 60% of patients were positive for HRHPV.
- After adjustment, patients with HPV positive OPC had 89% reduction in risk of death (HR = 0.11, 95% CI 0.05-0.25), and an 85% reduction in risk of disease progression (HR = 0.15 95% CI 0.07-0.30).
- The prevalence of HPV 16 in OPC indicates the potentially significant impact of prophylactic immunisation on this increasingly incident disease.

Abstract

Oropharyngeal cancer (OPC) is increasing on a global scale, including the component driven by high-risk human papillomavirus (HR-HPV); contemporary data that provide insight into the prognosis of this disease in addition to the fraction attributable to HR-HPV are essential to inform primary and secondary disease management strategies. A population-based cohort of 235 patients diagnosed with OPC between 2013-15 in Scotland was assessed for HPV status using molecular genotyping. Associations between HR-HPV status and key clinical and demographic variables were estimated using the Pearson chi-squared test. Rates of overall survival (OS) and progression-free survival (PFS) were estimated and visualized using Kaplan–Meier curves. HPV DNA (largely HPV 16) was identified in 60% of cases. After adjustment for age, gender, deprivation, smoking, alcohol consumption and tumour stage, patients with HR-HPV positive OPC had 89% reduction in risk of death (HR = 0.11, 95% CI 0.05-0.25), and an 85% reduction in risk of disease progression (HR = 0.15 95% CI 0.07-0.30). HPV positivity was not associated with age, deprivation or smoking status, whereas those who reported excess alcohol consumption were less likely to be HPV positive. The prevalence of HPV-associated OPC is high in Scotland and strongly associated with dramatically improved clinical outcomes including survival. Demographic/behavioural variables did not reliably predict HPV positivity in this cohort which underlines the importance of laboratory confirmation. Finally, the dominance of HPV 16 in OPC indicates the significant impact of prophylactic immunisation on this disease.

Keywords: HPV; oropharyngeal; cancer; prognosis; prevalence

Introduction

Oropharyngeal cancer (OPC) is increasing globally and the rate has doubled in the past 15 years in the United Kingdom with clinicians describing it as an 'epidemic' [1-3]. In Scotland, OPC is one of the most increasingly incident cancers – especially among men [4]. Tobacco use and alcohol consumption remain the major risk factors for head and neck cancers however, an increase in high-risk human papillomavirus (HR-HPV) driven OPC has also been observed [5,6]. Analyses of Scottish Cancer Registry head and neck cancer incidence trends over the past 40 years show that the rate of laryngeal cancer, which is strongly associated with tobacco consumption, has remained essentially stable. Oral cancer, which is associated with alcohol consumption, is steadily increasing, while OPC has risen comparatively more rapidly with a rate that has increased nearly 3-fold in recent years and is projected to rise further[7]. In relation to risk factors in head and neck cancer in Scotland these trends indicate a continued role of tobacco, an increasing role of alcohol, and a dramatic and relatively new role of the HPV [8].

The fraction of OPC associated with HPV varies significantly with geographic location; in the US prevalence is around 60% whereas in South America the attributable fraction is less than 5% [9]. A study of approximately 1500 archived OPC cases from 11 participating centres in the UK [10] (diagnosed between 2002 and 2011) showed approximately 50% were HR-HPV DNA-positive, largely for HPV type 16. Furthermore, the main HPV genotype identified in oral rinse samples from the general Scottish population was HPV 16 [11]. HPV is thought to be acquired through sexual exposure [12,13] although the natural history of HPV-associated OPC is not as well defined as other HPV-associated neoplasms such as cervix. Although the increase in OPC incidence is of clear concern, patients with HPV-driven OPC generally have a better prognosis compared to those patients who are HPV-negative [14]. Of note, the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S) has developed a new staging classification system informed by HPV-status which recognises the improved clinical outcomes' and this has now been incorporated into the 8th edition TNM classification [14].

Studies of North American populations suggest that the sociodemographic status of head and neck cancer patients may also be changing, with an increasing proportion of patients with OPC diagnosis being younger and more socioeconomically affluent [15]. This phenomenon is not mirrored in Scotland, since recent national cancer registry data show that patients from the most deprived areas consistently had the highest rates of OPC [8]. While the HPV status of OPCs is not available in Scottish cancer registry data, the association between deprivation and cancer rates may reflect the overwhelming influence of tobacco and alcohol consumption in head and neck cancer oncogenesis in Scotland. The Scottish population has historically had a high rate of smoking, with 45% of adults reporting as current or ex-regular cigarette smokers (as of 2016), with about 60% residing in the most deprived areas [16]. Excessive alcohol consumption in Scotland is also high with one in four adults consuming harmful levels in 2016 [16].

Prior to 2013, HPV testing of OPC in Scotland was performed opportunistically at the treating clinician's request, thereafter it was offered as a service to all Scottish health boards via the National

reference laboratory facility. This evaluation is one of the first to assess outcomes in a prospective, population based cohort of OPC patients, where HPV genotyping has been performed by a standardised methodology in a centralised location. We present data on the prevalence of HPV in OPC in Scotland and the association with key social variables and clinical indicators/outcomes. Furthermore, we investigate whether improved outcome associated with HPV-driven OPC is reflected in populations where rates of tobacco use and alcohol are particularly high, such as the West of Scotland.

Materials and Methods

Dimension and characteristics of patient cohort

All OPCs, including sub-sites of the tonsil, base of tongue, soft palate, and pharyngeal walls diagnosed in the West of Scotland Cancer Network between April 2013 and June 2015 underwent pathology review and prospective HPV genotyping as part of routine clinical care. The Health Boards included in the present analysis covered the following locations: West Dunbartonshire; East Dunbartonshire; East Renfrewshire; Glasgow City; Inverclyde, Renfrewshire, Forth Valley, Lanarkshire, Ayrshire and Arran which cover a population of approximately 2.5 million people. All individuals accessing health care in Scotland are assigned a unique 10-digit number, which allows linkage of clinical, social and laboratory data. Sociodemographic and clinical data were extracted from the West of Scotland Cancer Network Head and Neck Cancer Quality Performance Indicators, which are collected by all health boards in Scotland and used to drive quality improvement in cancer care across NHS Scotland and clinical records. The variables collected were: Date of diagnosis - taken as date of initial diagnostic biopsy sample collection, age at diagnosis, cancer stage; 7th edition TNM classification (TNM), 8th edition TNM classification for HPV positive OPCs/International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S) [14] which takes into account HPV status, treatment modality, date of relapse if occurred and if applicable date and cause of death, smoking status (never v. ever) at time of diagnosis and self-reported alcohol excess. Alcohol excess is defined by NHS Scotland as consuming alcohol at ≥ 21 units or more per week for men and ≥ 14 units per week for women] or documentation of “heavy”, “excessive” or “dependency” on alcohol within clinical records). In addition, area-based socioeconomic status was obtained - via the Scottish Index of Multiple Deprivation (SIMD) where 1 and 5 are the most and least deprived respectively. Data were extracted by treating clinicians and all patient identifiable data were removed prior to statistical analysis. Study governance and ethical considerations were through NHS Greater Glasgow and Clyde Research and Development Office, the Clinical Effectiveness Team and a data sharing agreement with the West of Scotland Cancer Network, NHS. Data was censored at November 2016

Nucleic acid extraction & HPV genotyping

Formalin fixed, paraffin-embedded (FFPE) block was selected and a 10 μ m section obtained for nucleic acid extraction. Nucleic acid extraction was performed using reagents within the DNA mini kit (Qiagen, Hilde Germany) with an adaptation to the protocol to maximise recovery of HPV DNA [17]. Subsequently, HPV genotyping was performed using the PCR and luminex based Optiplex HPV Genotyping test (Diamex, Heidelberg, Germany). This assay detects 24 HPV types including all

established HR types and, as a check for specimen adequacy, incorporates a cellular housekeeping control (betaglobin). This assay was used for the recent UK prevalence study of 1500 OPC referred to earlier [10]. Agreement of the this assay with p16INK4a immunohistochemistry has been shown to be 90% in oropharyngeal samples with no significant difference in the distribution of discordant results between the two tests. Furthermore, positivity according to this assay has been shown to correlate with cause-specific survival in Scottish cohorts as reported in Wells et al (2015) [10, 18]. All testing was performed at a centralised reference laboratory.

Analysis of HPV status with clinical outcomes

Associations between HR-HPV status and clinical and demographic variables were estimated using the Pearson chi-squared test. Both unadjusted and adjusted odds ratios (ORs) for HPV positivity and 95% confidence intervals (CIs) were calculated using logistic regression. Linear trend test was performed to investigate whether there was an increasing trend in the risk of HPV positive OPC with increasing age. Rates of overall survival (OS) and progression-free survival (PFS) were determined and univariate comparisons visualized using Kaplan–Meier curves. The univariate impact of each variable on survival was measured using Cox proportional-hazards regression. An adjusted model was created to obtain the adjusted hazard ratios for HR-HPV status with adjustment of the following covariates: gender, age at diagnosis (<50, 50-59, 60-69, 70-79 and 80+), SIMD, smoking and alcohol status and TNM classification 7 of cancer. Subset analysis on the HPV+ patients were carried out to obtain univariate and adjusted hazard ratio for ICON stage.

All statistical analysis was carried out using R version 3.2.3. All variables with P-values <0.05 were considered to be statistically significant.

Results

Description of cohort

A total of 235 patients were diagnosed with OPC between April 2013 and June 2015. Technically valid HPV results were obtained for 229 patients with 6 excluded due to non- amplification of the cellular housekeeping gene. Only 22 % of the 229 OPC patients were female and the median age was 60 (IQR 54-69). Most of the cohort was resident in a deprived area (37.6% in SIMD1 and 21% in SIMD2). The majority reported having ever smoked tobacco (65%) with 31% reporting drinking alcohol to excess (Table 1).

HPV positivity and association with extrinsic risk factors

HPV DNA was identified in 60% of the cases (136/229). Single infections with 16, 18, 33, 35 were identified in 127, 2, 1, and 1 case, respectively. The occurrence of multiple infections of 16/6, 16/59, 18/82, 6/16/33 and 18/59/82 all occurred in a single case each. All bar one of the HPV positive cases included at least 1 established HR-HPV type.

Influence of gender and risk factors are summarised in Table 1. Men were twice as likely as women to have an HPV positive tumour (OR 2.44, 95% CI 1.18-5.05, $P=0.02$). Those who reported drinking alcohol to excess were 70% less likely to be HPV positive (OR 0.30, 95% CI 0.14-0.63, $P=0.001$). HPV positivity was not associated with social deprivation as measured by SIMD ($P = 0.2$) or age (linear trend $P = 0.7$), or smoking status ($P = 0.1$).

HPV status and survival

A total of 35 patients were excluded from the survival analysis: one was lost to follow-up and 34 received treatment intent of best support palliative care due to frailty and were unable to tolerate treatment. Post-exclusions, the median follow-up time of the remaining cohort after OPC diagnosis was 2.2 years (range from 19 days to 3.4 years). In total, 23% patients (45/194) died and 28% patients (55/194) had disease progression during the follow-up period. One-year OS rate for HPV negative patients was 75.7% while for HPV positive patients OS was 95.2%. One-year PFS rate for HPV negative and HPV positive patients was 67.1% and 92.7%, respectively (Figures 1 and 2). One-year OS rates for the patients who smoked was 86.4% compared with 90.2% for the patients who reported never smoking. One-year OS rate for the patients who drank alcohol to excess was 80.4% compared with 91.5% for those who did not. In our data we observed an increase in the point estimates for death and disease free survival as TNM classification increased from stage 1 to 4, but use of ICON stage for the HPV positive population was not discriminatory.

Univariate analysis also showed that HPV negative status and alcohol consumption were significantly associated with increased risk of death (both $P<0.001$, Table 2). After adjustment for age, gender, SIMD, smoking and drinking status and tumour stage, patients with HR-HPV positive OPC had 89% reduction in risk of death (HR = 0.11, 95% CI 0.05-0.24, $P<0.001$, Table 2), and had 84% reduction in risk of disease progression (HR = 0.15, 95% CI 0.07-0.30, $P<0.001$, Table 3) compared with those with HPV negative OPC. The risk of death increased with age in the fully adjusted model. Patients who reported drinking alcohol to excess had 2.3 times the risk of death (HR OS = 2.33, 95% CI 1.06-5.18, $P=0.04$) compared with those who did not drink alcohol to excess.

Discussion

We have conducted a detailed population-based evaluation to examine the impact of demographic, behavioural, and viral factors associated with OPC in a context where both disease prevalence and non-viral risk factors (alcohol consumption and smoking) are high. We have demonstrated that HR-HPV prevalence among OPCs in the West of Scotland was 60% and that HR-HPV positivity was higher in males compared to females, and lower amongst those who reported drinking alcohol to excess. We also confirmed that in our population HR-HPV status was strongly associated with improved overall and progression-free survival. It was of interest that individuals reporting tobacco exposure were as likely to have cancers associated with HR-HPV as those individuals who reported no history of tobacco use - a finding at variance with other previously reported UK data [19].

Studies suggest that incidence of HR-HPV detection in OPCs varies widely depending on geographic location and period of time. We report HR-HPV rates of 49% among women and 62.4% among men,

with an overall positivity of 60%. This is broadly in line with the UK based results of Schache et al [3] and reflects a more recent period of assessment. Beyond the UK, studies of HR-HPV prevalence in OPCs in the most recent decade reports range from 6.1% in Spain [20], 38% in the Netherlands [21] and 62% in Denmark [22]. US estimates are consistently higher at around 60-70% [9]. A confounder to cross-study comparison is the different methods by which HPV positive status is defined, which vary across studies and include nucleic acid amplification tests, immunohistochemistry with p16INK4a, *in-situ* hybridisation and combinations thereof. In this work we used a sensitive PCR-based assay to confirm HPV status rather than p16INK4a; this assay has been shown to have a high level of agreement (90%) with p16INK4a immunohistochemistry, with no difference in the distribution of discordant results in OPC cases. Furthermore, HPV status determined by this assay has been shown to be independently associated with disease specific survival as indicated in previous studies, national audit and the data outlined in the present manuscript [10,18]. Thus, although testing with multiple markers/chemistries for HPV status provides further validation, we are confident that the assay is a robust and credible marker of HPV status. Additionally, the advantage of this approach is that it also provides information on type specific prevalence to allow the monitoring of epidemiological trends.

Country-specific data on the attributable fraction of HPV-associated disease are important as they will inform the decisions surrounding the utility and cost effectiveness of HPV vaccination including gender neutral vaccination. Certainly, significant impact of the vaccine on HR-HPV prevalence and disease outcomes including high grade cervical intraepithelial neoplasia (CIN2+) has already been observed in young women attending for screening in Scotland [23,24]. As reports suggest that HPV vaccination induces HPV antibodies in the oral cavity it is reasonable to assume that the vaccine will ultimately have an impact on OPC incidence [25,26]. This may be realised more rapidly in a gender neutral programme given that we and others have shown a significantly higher prevalence of OPCs associated with HPV in men compared to women [9].

We report an inverse association between HPV positivity and excess alcohol consumption. No other factor including social deprivation or cancer stage was associated with viral status. This is an interesting and important observation as it indicates that in Scotland, patient-related demographic and clinical factors cannot be reliably used to predict the HPV status of patients OPCs. Furthermore, we did not observe an inverse relationship between HPV positivity and smoking status unlike other studies [9] and this may have been affected by the high smoking rates and the socio-economic status of our study population (Table 1).

In our data TNM classification 7 was more predictive of outcome than the new staging system that takes into account HPV status, although numbers were small. The British Association of Head and Neck Oncologists (BAHNO) have raised concerns of the use of TNM 8 and have suggested TNM 7 continues to be recorded. While the new staging system reflects improved understanding of cancer biology and clinical outcome of HPV-positive OPCs, further research is required to define if TNM 8 is generalisable to all populations and can be used to change treatment decisions.

In the adjusted analysis HPV status was strongly associated with improvement in overall and progression free survival during a median of 2-years follow up. For individuals whose disease recurs, the median time to progression was similar for HPV positive and HPV negative OPCs, with most people experiencing disease progression in the first year after completion of therapy [27]. The improvement

in survival associated with HPV positive disease is in accordance with other studies of OPC; D'Souza et al (2016) recently reported a 66% reduction in the hazard of death among HPV positive OPC compared to HPV negative cases [28] and in other HPV-associated cancers [29,30]. It has been hypothesised that improved prognosis in HPV positive cancers may be due to better response rates to treatment through increased sensitivity to radiation and host immune response to the tumour [31]. While treatment for HPV positive and negative OPCs remains the same in many settings, the results of de-intensifying treatment trials in HPV positive OPC will be informative for future evidence-based management strategies [32]. The reduction in survival with increasing age and heavy alcohol consumption has implications for the ability to deliver and tolerate curative treatment, which may impact survival. Cause of death was out with the scope of the present study but nutritional factors and co-morbidities in these patient groups should be further evaluated.

Conclusion

In this evaluation of OPC patients in whom the prevalence of traditional risk factors of drinking and smoking was high; 60% of tumours were HPV positive with positivity dominated by HPV type 16. While we confirmed that in our population HR-HPV status was strongly associated with improved overall and progression-free survival, HPV status could not be reliably predicted by demographic/clinical characteristics alone emphasising the need for laboratory confirmation. While primary prevention of most OPCs through vaccination is likely to exert a significant influence on the burden of this disease in time, in the shorter term, Scotland must address other interventions to promote healthy living in order to reduce excessive alcohol consumption and smoking. Such interventions if successfully implemented, would have far-reaching benefits beyond the reduction of OPC.

Funding

Cancer Research UK, Development fund.

Acknowledgments

We would like to thank Julie Macdonell and Ian Downie, Department of Pathology, The Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, for assistance with data extraction and members of the Scottish HPV Reference Laboratory for practical support.

References

1. Hussein AA, Helder MN, de Visscher JG, Leemans CR, Braakhuis BJ, de Vet HCW, Forouzanfar T. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review. *Eur J Cancer* 2017; **82**: 115-127.
2. Mehanna H, Franklin N, Compton N, Robinson M, Powell N, Biswas-Baldwin N, Paleri V, Hartley A8, Fresco L, Al-Booz H, Junor E, El-Hariry I, Roberts S, Harrington K, Ang KK, Dunn J, Woodman C. Geographic variation in human papillomavirus-related oropharyngeal cancer: data from 4 multinational randomized trials. *Head Neck* 2016; **38**: E1863-9.
3. Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck squamous cell cancer: a tale of three cancers? *Clin Otolaryngol* 2018 May 16. doi: 10.1111/coa.13144 [Epub ahead of print].

4. Junor EJ, Kerr GR, Brewster DH. Oropharyngeal cancer. Fastest increasing cancer in Scotland, especially in men. *BMJ* 2010; **340**: c2512 doi:10.1136/bmj.c2512.
5. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol* 2013; **31**: 4550-9.
6. Winn DM, Lee YC, Hashibe M, Boffetta P; INHANCE consortium. The INHANCE consortium: toward a better understanding of the causes and mechanisms of head and neck cancer. *Oral Dis* 2015; **21**: 685-93.
7. <http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Head-and-Neck/> [accessed 30th May 2018]
8. Purkayastha M, McMahon AD, Gibson J, Conway DI. Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012) – a socioeconomic perspective. *Oral Oncol* 2016; **61**: 70-5.
9. Anantharaman D, Abedi-Ardekani B, Beachler DC, Gheit T, Olshan AF, Wisniewski K, et al. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. *Int J Cancer* 2017; **140**: 1968-1975.
10. Schache AG, Powell NG, Cuschieri KS, Robinson M, Leary S, Mehanna H, et al. HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. *Cancer Res* 2016; **76**: 6598-606.
11. Conway DI, Robertson C, Gray H, Young L, McDaid LM, Winter AJ, et al. Human Papilloma Virus (HPV) Oral Prevalence in Scotland (HOPSCOTCH): A Feasibility Study in Dental Settings. *PLoS One* 2016; **11**: e0165847.
12. Anantharaman D, Muller DC, Ligiou P, Ahrens W, Holcátová I, Merletti F, et al. Combined effects of smoking and HPV16 in oropharyngeal cancer. *Int J Epidemiol* 2016; **45**: 752-61.
13. Schnelle C, Whiteman DC, Porceddu SV, Panizza BJ, Antonsson A. Past sexual behaviors and risks of oropharyngeal squamous cell carcinoma: a case-case comparison. *Int J Cancer* 2017; **140**: 1027-34.
14. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. *Lancet Oncol* 2016; **17**: 440-51.
15. Dahlstrom KR, Bell D, Hanby D, Li G, Wang LE, Wei Q, et al. Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. *Oral Oncol* 2015; **51**: 832-8.
16. <https://beta.gov.scot/publications/scottish-health-survey-2016-volume-1-main-report/> (Table 1.1 and 2.3 accessed 9th September 2018).
17. Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. *J Mol Diagn* 2011; **13**: 377-81.

18. Wells LA, Junor EJ, Conn B, Pattle S, Cuschieri K. Population-based p16 and HPV positivity rates in oropharyngeal cancer in Southeast Scotland. *J Clin Pathol*. 2015 Oct;68(10):849-52
19. Evans M, Newcombe R, Fiander A, Powell J, Rolles M, Thavaraj S, et al.. Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. *BMC Cancer* 2013; **13**: 220.
20. Rodrigo JP, Heideman DA, García-Pedrero JM, Fresno MF, Brakenhoff RH, Díaz Molina JP, et al.. Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). *Int J Cancer* 2014; **134**: 487-92.
21. Henneman R, Van Monsjou HS, Verhagen CV, Van Velthuisen ML, Ter Haar NT, Osse EM, et al. Incidence Changes of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma and Effects on Survival in the Netherlands Cancer Institute, 1980-2009. *Anticancer Res* 2015; **35**: 4015-22.
22. Carlander AF, Grønhøj Larsen C, Jensen DH, Garnæs E, Kiss K, Andersen L, et al. Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014. *Eur J Cancer* 2017; **70**: 75-82.
23. Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. *Lancet Infect Dis* 2017; **17**: 1293-302.
24. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al.. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. *Br J Cancer* 2014; **111**: 1824-30.
25. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. *PLoS One* 2013; **8**: e68329.
26. Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, et al. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. *J Infect Dis* 2016; **214**: 1276-83.
27. Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. *J Clin Oncol*. 2014 Oct 20;32(30):3365-73
28. D'Souza G, Anantharaman D, Gheit T, Abedi-Ardekani B, Beachler DC, Conway DI, et al. Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents. *Oral Oncol* 2016; **62**: 20-7.
29. Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, et al. HPV status and favourable outcome in vulvar squamous cancer. *Int J Cancer* 2017; **140**: 1134-1146.
30. Cuschieri K, Brewster DH, Graham C, Nicoll S, Williams AR, Murray GI, et al. Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer. *Int J Cancer* 2014; **135**: 2721-6.

31. Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. *Lancet Oncol* 2017; **18**: 803-11.
32. Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? *Clin Transl Radiat Oncol*. 2017; **8**: 4-11.

Variable	Level	Number (N = 229)*		HR-HPV pos (N= 136)		Unadjusted				Adjusted (full model)**			
		n	%	n	%	OR	95% CI lower	95% CI upper	p values	OR	95% CI lower	95% CI upper	p values
Sex	Female	51	22.3	25	49.0	1				1			
	Male	178	77.7	111	62.4	1.72	0.92	3.23	0.09	2.44	1.18	5.05	0.02
Age	<50	27	11.8	20	74.1	1							
	50-59	86	37.6	58	67.4	0.73	0.27	1.92	0.5				
	60-69	60	26.2	30	50.0	0.35	0.13	0.95	0.04				
	70-79	49	21.4	25	51.0	0.36	0.13	1.02	0.05				
	80 and over	7	3.1	3	42.9	0.26	0.05	1.48	0.1				
	Age in years (19-91)	229				0.97	0.95	1	0.04 (trend)	0.99	0.97	1.02	0.7 (trend)
SIMD	1: most deprived	86	37.6	44	51.2	1				1			
	2	48	21.0	27	56.3	1.23	0.6	2.5	0.6	1.01	0.44	2.33	1.0
	3	35	15.3	26	74.3	2.76	1.16	6.57	0.02	4.24	1.45	12.35	0.01
	4	29	12.7	20	69.0	2.12	0.87	5.18	0.1	1.75	0.64	4.75	0.3
	5: least deprived	19	8.3	13	68.4	2.07	0.72	5.94	0.2	1.39	0.4	4.86	0.6
	Missing	12	5.2	6	50.0					0.94	0.18	5	0.9
Smoking status	No	63	27.5	50	79.4	1				1			
	Yes	149	65.1	77	51.7	0.28	0.14	0.55	0.0003	0.52	0.23	1.17	0.1
	Missing	17	7.4	9	52.9					1.12	0.18	6.94	0.9
Alcohol status	No	129	56.3	91	70.5	1				1			
	Yes	71	31.0	30	42.3	0.31	0.17	0.56	0.0001	0.3	0.14	0.63	0.001
	Missing	29	12.7	15	51.7					0.45	0.12	1.69	0.2
Smoking & Alcohol	No/either	138	60.3	98	72.1	1							
	Both	66	28.8	27	19.8	0.28	0.15	0.52	0.00005				
	Missing	25	10.9	11	8.1								
TNM stage	1	13	5.7	2	15.4	1				1			
	2	26	11.4	11	42.3	4.03	0.74	21.98	0.1	10.94	1.6	74.91	0.01
	3	20	8.7	13	65.0	10.21	1.75	59.65	0.01	23.37	3.09	176.86	0.002
	4a	148	64.6	100	67.6	11.46	2.44	53.74	0.002	23.8	3.99	141.98	0.001

4b	12	5.2	6	50.0	5.5	0.84	36.2	0.08	17.65	1.94	160.87	0.01
4c	4	1.7	2	50.0	5.5	0.46	65.16	0.2	8.38	0.63	112.14	0.1
Missing	6	2.6	2	33.3					5.81	0.39	86.24	0.2

*Valid HPV results available for 229/235 cases

**An Adjusted for all variables in the table with the exception of treatment. It is highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity.

Table 1 Factors associated with high-risk human papillomavirus (HR-HPV) among OPC cases

Variable	Level	Number (N = 194)*	Number with all cause death	Person years follow up	Rate per 100 person years	95% CI Lower	95% CI Upper	Univariate HR	Lower 95% CI	Upper 95% CI	p value	Adjusted (full) HR**	Lower 95% CI	Upper 95% CI	p value
HR-HPV status	Negative	70	31	132.7	23.4	15.9	33.1	1.00				1.00			
	Positive	124	14	269.8	5.2	2.8	8.7	0.20	0.11	0.39	<0.00001	0.11	0.05	0.24	<0.00001
Sex	Female	39	7	80.8	8.7	3.5	17.9	1.00				1.00			
	Male	155	38	321.8	11.8	8.4	16.2	1.33	0.59	2.99	0.5	1.04	0.44	2.69	0.9
Age	<50	25	1	60.3	1.7	0.04	9.2	1.00				1.00			
	50-59	79	13	172.2	7.5	4.0	12.9	4.45	0.58	34.04	0.2	1.55	0.34	14.88	0.6
	60-69	50	12	98.5	12.2	6.3	21.3	7.25	0.94	55.82	0.06	1.92	0.40	18.93	0.5
	70-79	38	18	69.6	25.9	15.3	40.9	14.59	1.94	109.70	0.01	10.39	2.42	97.07	0.0007
	80 and over	2	1	2.0	48.9	1.2	272.6	28.87	1.80	463.90	0.02	104.44	6.53	1744.56	0.003
SIMD	1: most deprived	68	20	132.0	15.1	9.3	23.4	1.00				1.00			
	2	37	6	78.4	7.7	2.8	16.7	0.51	0.20	1.26	0.1	0.66	0.21	1.81	0.4
	3	33	7	70.0	10.0	4.0	20.6	0.57	0.23	1.42	0.2	1.30	0.47	3.25	0.6
	4	27	9	53.1	17.0	7.8	32.2	1.11	0.51	2.45	0.8	2.77	1.09	6.70	0.03
	5: least deprived	18	3	38.6	7.8	1.6	22.7	0.51	0.15	1.73	0.3	0.91	0.23	2.70	0.9
	Missing	11	0	30.4	0.0	0.0	12.1					0.11	0.00	1.18	0.07
Smoking status	No	61	10	129.0	7.8	3.7	14.3	1.00				1.00			
	Yes	118	34	235.7	14.4	10.0	20.2	2.06	0.99	4.30	0.05	1.64	0.64	4.45	0.3
	Missing	15	1	37.9	2.6	0.1	14.7					4.23	0.28	48.34	0.3
Alcohol status	No	118	18	256.9	7.0	4.2	11.1	1.00				1.00			
	Yes	51	24	84.7	28.3	18.1	42.1	4.34	2.32	8.12	<0.00001	2.32	1.06	5.18	0.04
	Missing	25	3	61.0	4.9	1.0	14.4					0.69	0.12	2.82	0.6
TNM stage	1	13	2	27.6	7.2	0.9	26.2	1.00				1.00			
	2	23	10	41.2	24.3	11.6	44.7	3.20	0.70	14.64	0.1	3.20	0.86	17.30	0.08
	3	20	2	45.5	4.4	0.5	15.9	0.60	0.09	4.29	0.6	3.85	0.53	28.22	0.2
	4a-c***	133	31	273.5	11.3	7.7	16.1	1.50	0.36	6.26	0.6	9.97	2.57	56.41	0.0005
	Missing	5	0	14.8	0.0	0.0	24.9								
ICON stage*****	1	16	3	34.3	8.7	1.8	25.6	1.00							

2	71	4	156.8	2.6	0.7	6.5	0.30	0.07	1.34	0.1
3-4****	36	7	75.7	9.2	3.7	19.0	0.97	0.24	3.87	1.0
Missing	1	0	3.0	0.0	0.0	122.9				

* individual removed from OS analysis as lost follow up (no date of death and no date of alive); individuals also removed from OS analysis as treatment = BSC

**An Adjusted for all variables in the table with the exception of ICON stage. They are highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity.

***For TNM stage, 4a-c combines the levels 4a (126 cases, 30 died), 4b (6 cases, 1 died) and 4c (1 case, 0 died).

****For ICON stage, 3-4 combines the levels 3 (35 cases, 7 died) and 4 (1 case, 0 died).

*****Only select HRPV+ cases N=124

Table 2 Hazard ratios for OS

Variable	Level	Number (N = 194)	Number recur or die	Person years follow up	Rate per 100 person years	95% CI Lower	95% CI Upper	Univariate HR	Lower 95% CI	Upper 95% CI	p value	Adjusted (full) HR*	Lower 95% CI	Upper 95% CI	p value
HR-HPV status	Negative	70	35	129.6	27.0	18.8	37.6	1.00				1.00			
	Positive	124	20	263.2	7.6	4.6	11.7	0.27	0.16	0.48	<0.00001	0.15	0.07	0.30	<0.00001
Sex	Female	39	9	79.8	11.3	5.2	21.4	1.00				1.00			
	Male	155	46	313.0	14.7	10.8	19.6	1.30	0.64	2.66	0.5	0.98	0.47	2.24	1.0
Age	<50	25	2	60.1	3.3	0.4	12.0	1.00				1.00			
	50-59	79	17	168.1	10.1	5.9	16.2	3.12	0.72	13.54	0.1	1.46	0.41	7.79	0.6
	60-69	50	14	97.9	14.3	7.8	24.0	4.37	0.99	19.25	0.051	1.59	0.42	8.71	0.5
	70-79	38	21	64.6	32.5	20.1	49.7	9.55	2.23	40.91	0.002	8.65	2.57	44.83	0.0002
	80 and over	2	1	2.0	48.9	1.2	272.6	15.93	1.43	176.98	0.02	45.72	3.49	454.44	0.007
SIMD	1: most deprived	68	23	129.0	17.8	11.3	26.8	1.00				1.00			
	2	37	9	76.7	11.7	5.4	22.3	0.65	0.30	1.41	0.3	1.06	0.42	2.49	0.9
	3	33	9	67.1	13.4	6.1	25.5	0.67	0.30	1.49	0.3	1.35	0.55	3.05	0.5
	4	27	9	52.1	17.3	7.9	32.8	0.95	0.44	2.05	0.9	2.10	0.85	4.88	0.1
	5: least deprived	18	5	37.5	13.3	4.3	31.1	0.76	0.29	2.00	0.6	1.34	0.45	3.39	0.6
	Missing	11	0	30.4	0.0	0.0	12.1					0.05	0.00	0.49	0.01
Smoking status	No	61	12	125.4	9.6	4.9	16.7	1.00				1.00			
	Yes	118	41	231.3	17.7	12.7	24.0	2.00	1.03	3.90	0.04	1.70	0.73	4.12	0.2
	Missing	15	2	36.0	5.5	0.7	20.0					11.43	1.30	95.61	0.0003
Alcohol status	No	118	23	250.9	9.2	5.8	13.8	1.00				1.00			
	Yes	51	27	82.3	32.8	21.6	47.7	3.84	2.17	6.79	<0.00001	2.08	0.99	4.33	0.1
	Missing	25	5	59.5	8.4	2.7	19.6					0.66	0.13	2.39	1.0
TNM stage	1	13	2	27.1	7.4	0.9	26.7	1.00				1.00			
	2	23	13	37.9	34.3	18.3	58.7	4.58	1.03	20.37	0.05	4.55	1.25	24.56	0.02
	3	20	4	44.8	8.9	2.4	22.9	1.20	0.22	6.53	0.8	4.69	0.94	29.13	0.06
	4a-c**	133	36	268.2	13.4	9.4	18.6	1.72	0.41	7.16	0.5	9.26	2.41	52.15	0.001
	Missing	5	0	14.8	0.0	0.0	24.9					0.61	0.00	12.65	0.8
ICON stage****	1	16	4	32.0	12.5	3.4	32.1	1.00							

2	71	7	155.1	4.5	1.8	9.3	0.37	0.11	1.26	0.1
3-4***	36	9	73.1	12.3	5.6	23.4	0.92	0.28	3.07	0.9
Missing	1	0	3.0	0.0	0.0	122.9				

*An Adjusted for all variables in the table with the exception of ICON stage. They are highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity.

**For TNM stage, 4a-c combines the levels 4a (126 cases, 34 died/recur), 4b (6 cases, 2 died/recur) and 4c (1 case, 0 died/recur).

***For ICON stage, 3-4 combines the levels 3 (35 cases, 9 died/recur) and 4 (1 case, 0 died/recur).

*****Only select HRHPV+ cases N=124

Table 3 Hazard ratios for PFS

Variable	Level	OS				PFS			
		HR	Lower 95% CI	Upper 95% CI	p value	HR	Lower 95% CI	Upper 95% CI	p value
Sex	Female	1.00				1.00			
	Male	0.55	0.11	3.36	0.48	0.53	0.14	2.34	0.378
Age	<50	1.00				1.00			
	50-59	3.66	0.29	529.78	0.36	4.95	0.52	667.62	0.196
	60-69	8.56	0.58	1313.37	0.13	8.31	0.65	1199.88	0.113
	70-79	18.45	1.62	2678.93	0.01	21.83	2.27	2974.37	0.004
	80 and over	160.13	0.53	58517.87	0.07	53.83	0.23	12923.17	0.119
SIMD	1: most deprived	1.00				1.00			
	2	1.99	0.16	17.15	0.55	3.65	0.66	21.41	0.135
	3	3.86	0.89	20.02	0.07	4.57	1.23	20.60	0.023
	4	3.99	0.77	22.28	0.10	3.97	0.77	21.01	0.096
	5: least deprived	1.45	0.01	21.12	0.82	3.77	0.32	29.32	0.252
Smoking status	No	1.00				1.00			
	Yes	1.95	0.38	13.20	0.43	1.54	0.42	6.37	0.518
Alcohol status	No	1.00				1.00			
	Yes	5.30	1.28	28.40	0.02	5.19	1.49	20.62	0.009
ICON stage	1	1.00				1.00			
	2	0.78	0.14	4.81	0.78	0.91	0.23	4.10	0.897
	3-4	2.88	0.68	15.18	0.15	1.92	0.52	8.07	0.329

Table A1 Adjusted hazard ratios for ICON for HRHPV+ patients only (N=124)

Figure 1 Survival plots for OS (plot for ICON stage are only for the subset of HRHPV+ patients)




Figure 2 Survival plots for PFS (plot for ICON stage are only for the subset of HRHPV+ patients)

